The Role of Lapatinib in the Preoperative Therapy of Breast Cancer

被引:0
|
作者
Hirsh, Rebecca L. [1 ,2 ]
DeMichele, Angela [1 ,2 ,3 ]
机构
[1] Univ Penn, Dept Med, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
Neoadjuvant; HER2; Lapatinib; Trastuzumab; Breast cancer; PATHOLOGICAL COMPLETE RESPONSE; PHASE-II TRIAL; NEOADJUVANT THERAPY; ADJUVANT CHEMOTHERAPY; STAGE-II; TRASTUZUMAB; PLUS; DOCETAXEL; PACLITAXEL;
D O I
10.1007/s11912-011-0206-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Preoperative or neoadjuvant chemotherapy is a well-established modality in the treatment of nonmetastatic breast cancer. Patients initially considered inoperable may be able to achieve operable status after preoperative chemotherapy and patients initially considered not to be candidates for breast conservation may convert to breast conservation status. Human epidermal growth factor receptor 2 (Her2)-positive tumors have been shown to have a more aggressive course including early local relapse and metastasis when compared to Her2-negative breast cancers, but the optimal use of Her2-targeted agents is constantly evolving as new agents become available. Preoperative studies allow us to quickly assess the activity of new agents and combinations for particular biological subsets of breast cancer.
引用
收藏
页码:44 / 47
页数:4
相关论文
共 50 条
  • [21] Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
    Taskar, Kunal S.
    Rudraraju, Vinay
    Mittapalli, Rajendar K.
    Samala, Ramakrishna
    Thorsheim, Helen R.
    Lockman, Julie
    Gril, Brunilde
    Hua, Emily
    Palmieri, Diane
    Polli, Joseph W.
    Castellino, Stephen
    Rubin, Stephen D.
    Lockman, Paul R.
    Steeg, Patricia S.
    Smith, Quentin R.
    PHARMACEUTICAL RESEARCH, 2012, 29 (03) : 770 - 781
  • [22] HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
    Dent, Susan
    Oyan, Basak
    Honig, Amd
    Mano, Max
    Howell, Sacha
    CANCER TREATMENT REVIEWS, 2013, 39 (06) : 622 - 631
  • [23] Lapatinib in breast cancer
    Bilancia, D.
    Rosati, G.
    Dinota, A.
    Germano, D.
    Romano, R.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 30
  • [24] Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
    von Minckwitz, G.
    Eidtmann, H.
    Loibl, S.
    Blohmer, J. -U.
    Costa, S. -D.
    Fasching, P. A.
    Kreienberg, R.
    Hilfrich, J.
    Gerber, B.
    Hanusch, C.
    Fehm, T.
    Strumberg, D.
    Solbach, C.
    Nekljudova, V.
    Untch, M.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 301 - 306
  • [25] Lapatinib for the treatment of breast cancer in the People's Republic of China
    Wang, Hongjiang
    ONCOTARGETS AND THERAPY, 2014, 7 : 1367 - 1373
  • [26] Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World
    Yu, Xingfei
    Wang, Chen
    Zheng, Yabing
    Miao, Beibei
    Hu, Jiejie
    Shao, Xiying
    Sheng, Liming
    Lin, Juan
    Ding, Yuqin
    Xuan, Haojun
    Ding, Yingying
    Gong, Lijie
    Feng, Weiliang
    Qin, Chengdong
    Chen, Daobao
    Yu, Yang
    Yang, Hongjian
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [27] Preoperative Systemic Therapy for Breast Cancer
    Kodali, Abhigna
    Gadi, Vijayakrishna K.
    SURGICAL CLINICS OF NORTH AMERICA, 2023, 103 (01) : 201 - 217
  • [28] Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer
    Melichar, Bohuslav
    Studentova, Hana
    Kalabova, Hana
    Vitaskova, Denisa
    IMMUNOTHERAPY, 2014, 6 (07) : 811 - 819
  • [29] Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
    Yang, Fan
    Huang, Xiang
    Sun, Chunxiao
    Li, Jianbin
    Wang, Biyun
    Yan, Min
    Jin, Feng
    Wang, Haibo
    Zhang, Jin
    Fu, Peifen
    Zeng, Tianyu
    Wang, Jian
    Li, Wei
    Li, Yongfei
    Yang, Mengzhu
    Li, Jun
    Wu, Hao
    Fu, Ziyi
    Yin, Yongmei
    Jiang, Zefei
    BMC CANCER, 2020, 20 (01)
  • [30] Lapatinib: new opportunities for management of breast cancer
    Liao, Julia
    Gallas, Michelle
    Pegram, Mark
    Slingerland, Joyce
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 79 - 91